New Horizon Health HK$781.7 million top-up placement of shares
We advised New Horizon Health on the top-up placement
Davis Polk advised New Horizon Health Limited on a top-up placement of 27,543,000 of its shares for a total consideration of approximately HK$781.7 million.
Davis Polk also advised New Horizon Health Limited on its HK$2.04 billion IPO in February 2021.
New Horizon Health is the pioneer in China’s colorectal cancer screening market with ColoClear, its proprietary, non-invasive, multi-target, FIT-DNA test, being the first and only molecular cancer screening test in China approved by NMPA, according to Frost & Sullivan.
The Davis Polk team included partner Yang Chu and associates Sarah Shi and Michelle Chow. Members of the Davis Polk team are based in Hong Kong office.
Copy link to share post